
==== Front
Cureus
Cureus
2168-8184
Cureus
2168-8184
Cureus Palo Alto (CA)

10.7759/cureus.67151
Pharmacology
Gastroenterology
Therapeutics
Evaluating Bempedoic Acid for Non-alcoholic Fatty Liver Disease: A Review of Preclinical and Clinical Research
Muacevic Alexander
Adler John R
Anasdeen S Mohamed 1
S Shahinaz 1
TM Vijayakumar 1
1 Department of Pharmacy Practice, College of Pharmacy, SRM Institute of Science and Technology, Chennai, IND
Vijayakumar TM vijayakm2@srmist.edu.in
18 8 2024
8 2024
16 8 e6715124 7 2024
18 8 2024
Copyright © 2024, Anasdeen S et al.
2024
Anasdeen S et al.
https://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
This article is available from https://www.cureus.com/articles/281683-evaluating-bempedoic-acid-for-non-alcoholic-fatty-liver-disease-a-review-of-preclinical-and-clinical-research
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent liver disorder globally, characterized by fat accumulation in liver cells, which can progress to inflammation, fibrosis, and cirrhosis. The disease predominantly affects individuals with obesity and high body mass index (BMI). It is a globally prevalent condition, with variations in incidence across different regions. The pathophysiology of NAFLD involves insulin resistance, metabolic disturbances, and genetic and gut microbial factors. Current treatments primarily focus on lifestyle modifications and a limited range of pharmacological options. Bempedoic acid (BA), a novel cholesterol-lowering agent, targets adenosine triphosphate (ATP)-citrate lyase to reduce low-density lipoprotein (LDL) cholesterol and has shown potential in managing NAFLD by decreasing liver fat accumulation and improving lipid profiles. BA's unique mechanism offers a promising add-on therapy, particularly for the patient’s intolerant to statins. Despite its potential, comprehensive clinical and preclinical studies are needed to further elucidate its efficacy and safety compared to other NAFLD treatments. Future research should focus on comparing BA with existing and emerging therapies to optimize its role in NAFLD management and enhance patient outcomes.

non-alcoholic steatohepatitis (nash)
non-alcoholic fatty liver disease
low-density lipoprotein (ldl) cholesterol
metabolic disorder
bempedoic acid
==== Body
pmcIntroduction and background

Non-alcoholic fatty liver disease (NAFLD) is the most common liver disease around the world. It is a chronic condition where fat accumulates in liver cells, leading to inflammation and pain with few or no symptoms in the early stages. As the disease advances, it can cause increased pain in the upper abdomen and may develop into non-alcoholic steatohepatitis (NASH), which can result in fibrosis and cirrhosis. Individuals who are overweight or with a body mass index (BMI) greater than 33 kg/m² are more likely to develop NAFLD according to the World Health Organization. The epidemiology of liver cirrhosis has been thoroughly examined in several developed nations across Europe and America. In many developing countries, the lack of sufficient data on the disease has led to less attention being paid to its mortality rate. The global health community is increasingly recognizing the need to manage risk factors for liver cirrhosis, particularly alcohol use and chronic infections with hepatitis B and C viruses. In its early stages, NAFLD exhibits no noticeable symptoms. As the illness worsens, though, people may feel fatigued, irritable, or have pain in their upper right abdomen. They can also develop an enlarged liver. Unexpected weight loss may also be seen by certain patients. In severe cases, NAFLD can lead to NASH, which can further lead to cirrhosis and decompensation. Early detection and management of NAFLD are crucial to prevent severe liver damage, cirrhosis, and liver dysfunction. NAFLD has a wide range of complex causes. The fundamental cause is insulin resistance, which is the body's cells' poor response to insulin, resulting in the accumulation of fat in the liver. This is often related to lifestyle factors; obesity, particularly excess weight around the abdomen, and diseases such as type 2 diabetes and high cholesterol are major contributors. Consuming excess sugar, processed carbohydrates, and unhealthy fats can cause fatty liver. Recent studies state that gut bacteria have a slight impact on fat accumulating in the liver [1]. Bempedoic acid (BA) is a cholesterol-lowering drug that blocks an enzyme called adenosine triphosphate (ATP) - citrate lyase - which helps produce cholesterol. Through this process, BA lowers cholesterol levels. Some studies show that BA can help prevent NAFLD from progressing to NASH [2].

Review

Pathophysiology

The primary cause of NAFLD is overnutrition, which results in the accumulation of fats in adipose and non-adipose tissues. Mostly due to insulin resistance, which results in uncontrolled lipolysis, which significantly reduces the liver's metabolic capacity. This imbalance results in metabolism leading to harmful lipids causing inflammation, lipid accumulation, and even cell death. Macrophages play a significant role in liver fibrosis, which results in chronic inflammation in liver tissues. The exact mechanism behind NAFLD is still unknown but the most predominant factors influencing NAFLD are metabolic, genetic, and gut microbial conditions. Genetic factors alone contribute up to 30-70% in disease risk based on the heritable component. Alteration in gut microbes can have a significant effect on NAFLD because of their vital role in lipopolysaccharides, and bile acid production which may contribute to inflammation in the liver and disease progression. Inflammatory responses, oxidative stress, and genetic predisposition are among the key factors contributing to the development of NAFLD. Additionally, metabolic disturbances, such as insulin resistance and dyslipidemia, along with lifestyle factors such as poor diet and sedentary behavior, further exacerbate the condition. Figure 1 represents the progression of the degrading liver due to NAFLD [3].

Figure 1 Progression of the degrading liver.

This image was inspired by the article by Bessone et al. (2019) and was recreated by the author [3].

Current treatment landscape

Non-pharmacological Management

Lifestyle changes, including adjustments to diet, exercise, and physical activity, are fundamental in managing NASH. The main objectives of these approaches are to control metabolic conditions and maintain a healthy body weight through methods, such as calorie restriction, time-restricted eating, and regular physical exercise.

Pharmacological Management

Pharmacological treatment is generally considered to address the underlying causes and to improve the over conditions. In patients with NAFLD, insulin sensitivity is the main and most common reason for the accumulation of fats in the liver. Many studies have been conducted and proven by Ratziu et al. [4] and Aithal et al. [5] that enhancing insulin sensitivity through administering drugs in the classes of thiazolidinediones improves insulin sensitivity in patients with NASH. A study conducted by Wang et al. [6] on vitamin E supplements proved that it had significant improvement in liver enzyme levels and reduced fibrosis in the long term. Yoon et al. [7] conducted a study on a combination of ursodeoxycholic acid and vitamin E in patients with NAFLD, and they recorded a significant improvement in liver recovery [7]. Research was conducted by Younossi et al. [8] on the use of obeticholic acid to treat NASH, and the findings indicate a noteworthy improvement in the patient's fibrosis and recovery [8]. A new investigation drug called tropifexor agonist of non-bile acid farnesoid X receptor inhibits bile acid synthesis and increases excretion, which ultimately results in less bile accumulation in the liver; hence, this drug is in its phase 2 trials and is expected to be used for the treatment of NASH [9]. Another promising drug treatment for NAFLD is peroxisome proliferator-activated receptors (PPAR) agonists, which are elafibranor and saroglitazar. Elafibranor showed a 19% NASH resolution without worsening fibrosis compared to 12% for placebo in a phase 2b trial [10]. As of the phase 3 results reported, elafibranor clearly has advantages in lowering the risk of NASH progressing to fibrosis or cirrhosis, but it has recorded many side effects in the trials, including abdominal pain, diarrhea, nausea, and vomiting [10]. Gawrieh et al. [11] conducted a 16-week trial with 106 NAFLD/NASH patients. Saroglitazar significantly reduced alanine transaminase (ALT) levels compared to a 3.4% increase with placebo. The 4 mg dose also improved liver fat content, adiponectin, insulin resistance, and triglycerides. Saroglitazar was well-tolerated, with a mean weight gain of 1.5 kg compared to 0.3 kg with placebo [11]. An oral THR-β agonist known as resmetirom received accelerated approval in March 2024 for the treatment of noncirrhotic NASH with moderate to advanced fibrosis in the United States. The drug is currently under review for regulatory approval in the European Union [12]. These are the most common and novel pharmacological treatments, which are in clinical practice, and few of them in clinical trials for the treatment of NAFLD and NASH.

Difference between BA and other drugs used in NAFLD

BA is a new medication primarily known for its lipid-lowering effects, particularly in reducing low-density lipoprotein (LDL) cholesterol levels, but it shows some promise in the management of NAFLD. The key mechanism of BA is inhibiting ATP-citrate lyase, which helps reduce hepatic fat accumulation and improve lipid profile. This has an indirect effect on patients with NAFLD. The mechanism of BA is different from other drugs commonly used for NAFLD. In contrast with pioglitazone, thiazolidinediones improves the sensitivity of insulin, which results in a direct effect on liver fat reduction. It is often limited by its side effects, including weight gain [4,5]. Obeticholic acid, a farnesoid X receptor agonist, largely targets bile acid metabolism, which has been shown to reduce inflammation and fibrosis in NASH patients rather than focusing on lipid metabolism [8]. Another drug liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist primarily used for diabetes, helps improve insulin sensitivity by promoting weight loss and shows some promise in treating NAFLD. BA can be used as an adjuvant therapy along with other drugs for the effective treatment of NAFLD [13].

Clinical efficacy and effectiveness

The clinical efficacy of BA for the treatment of NAFLD is still being explored. Here is a summary of the current understanding.

Lipid-Lowering Effect

BA primarily acts as a lipid-lowering agent by inhibiting ATP citrate lyase enzymes, leading to reduced LDL levels and cholesterol levels. This can indirectly have a superior effect on patients with NAFLD and NASH, especially with synchronic dyslipidemia. As the lipid profile improves, fat accumulation and overall metabolic syndrome reverses in the early stages [2].

Indirect Liver Benefits

BA reduces the fat content in the liver, by lowering cholesterol and LDL levels, which is an important aspect of NAFLD management. A few preclinical and clinical studies are listed below, which will provide a comprehensive outline of the efficacy of BA in the management of NAFLD.

Complementary Effectiveness

BA is commonly used in combination therapy with other lipid-lowering agents, including statins and non-statins lipid-lowering drugs. It is predominately used in patients with statin intolerance. It is more effective as an adjuvant therapy rather than monotherapy.

Safety Profile

It has a well-tolerated effect with a good safety profile. As an added advantage, it is a hydrophilic drug; hence, it has very little to zero effect on the liver, making it very compatible with treating patients with chronic conditions such as NAFLD and dyslipidemia [3].

Preclinical studies

The efficacy of BA in preclinical studies for NAFLD is still in the early stages. Animal models have shown promising effects on reducing liver fat and improving lipid metabolism. These studies indicate that BA decreases de novo lipogenesis and lowers hepatic fat accumulation in animal models. Table 1 provides an overview of BA's effectiveness in animal models.

Table 1 List of pre-clinical studies on the effectiveness of BA.

S.no	Author	Animal	Diet	Dose per day	Days	Observation	Ref	
1.	Desjardins et al.	C57BL/6J mice	High-fat high-fructose diet	10 mg/kg of BA and 70 µg/kg of liraglutide	112	The combination reduced up to 44% of fibrosis compared to liraglutide and a significant reduction in triglycerides and cholesterol 	[13]	
2.	Samsoondar et al.	Mice	High fat-containing diet	3 mg/kg 10 mg/kg 30 mg/kg	84	10& 30 mg/kg batch has significantly less cholesterol & triglycerides compared to the control group and liver enzymes	[14]	
3.	Burke et al.	Yucatan miniature pigs	High-fat high-calorie diet	120 mg/day 240 mg/day	160	It has a significant decrease in plasma lipid concentration up to 60% without altering the liver enzymes	[15]	
4.	Pinkosky et al.	Mice	High-fat high-calorie diet	30 mg/kg	84	It showed a remarkable difference in the lipid levels with no alteration in liver enzymes	[16]	

Clinical studies

NAFLD is a widespread global health issue, and recent research highlights the potential of BA in addressing this condition. The data presented in Table 2 demonstrate that BA, whether used alone or in combination with other agents, has achieved remarkable results in the management of dyslipidemia. This evidence suggests that BA is an excellent option for patients with NAFLD who are intolerant to statins, offering a viable alternative with relatively low toxicity. Its efficacy in improving lipid profiles while maintaining a favorable safety profile underscores its promising role in the comprehensive treatment of dyslipidemia and NAFLD.

Table 2 List of clinical studies on BA with placebo and other drugs.

S.no	Author	Groups + dose in mg	Total population	Ratio	Weeks	Observation	Ref	
1.	Ballantyne et al.	Bempedoic acid (180)	placebo	269	2:1	12	Significant decrease in LDL-C, apolipoprotein B, and C-reactive protein levels	[17]	
2.	Ballantyne et al.	BA+EZE (180+10)	EZE (10)	BA (180)	PO	301	2:2:2:1	12	BA+EZE produced a significantly greater effect which then followed BA alone reduced LDL-C levels.	[18]	
3.	Thompson et al.	BA (120)	BA (180)	BA+EZ (120+10)	BA+EZ (180+10)	EZ (10)	PO	322	4:4:4:4:1:1	12	48% reduction in LDL levels by BA+EZ (180mg) shows the significance of BA.	[19]	
4.	Gutierrez et al.	BA (80)	PO	BA (120)	PO	60	1:1:1:1	4	BA (120mg) reduced 43% LDL-C & 38% in BA compared with placebo	[20]	
5.	Shapiro et al.	BA in nonmetabolic disease 	PO in non-metabolic disease	BA in metabolic disease	PO in metabolic disease	2509	6:4 & 7:3	52	BA in non-metabolic disease reduced LDL-C even in metabolic disease it produced safe results without elevation of liver enzymes	[21]	
1037	536	648	288	

Future direction and research

Although existing research provides valuable insights, the current body of evidence available online is limited and does not encompass all aspects of BA's efficacy and safety. To gain a more comprehensive understanding of its potential, further research is essential. Conducting additional clinical studies and comparing BA with other dyslipidemic and NAFLD treatments will be crucial in elucidating its benefits and limitations. Such comparative analyses will help establish a clearer picture of BA's role in managing these conditions and guide its future applications in clinical practice.

Conclusions

In summary, NAFLD represents a significant global health challenge with complex etiologies and varying regional prevalence. While lifestyle modifications and existing pharmacological treatments offer some relief, the management of NAFLD and its progression to more severe conditions such as NASH remains a critical area of focus. BA, a novel lipid-lowering agent, has shown promising results in improving lipid profiles and potentially mitigating liver fat accumulation, presenting a viable option, especially for patients intolerant to statins. Despite the encouraging data, the full potential of BA in NAFLD management is still under investigation. There is a pressing need for further clinical research to better understand its efficacy and safety, particularly in comparison to other NAFLD and dyslipidemia treatments. Continued exploration and well-designed studies will be crucial in determining the optimal role of BA in the therapeutic landscape and ensuring it contributes effectively to the comprehensive management of NAFLD.

The authors sincerely thank SRM College of Pharmacy, SRMIST, for providing the resources.

Disclosures

Author Contributions

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following:

Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work.

Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work.

Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Concept and design:  Vijayakumar TM, Mohamed Anasdeen S, Shahinaz S

Acquisition, analysis, or interpretation of data:  Vijayakumar TM, Mohamed Anasdeen S, Shahinaz S

Drafting of the manuscript:  Vijayakumar TM, Mohamed Anasdeen S, Shahinaz S

Critical review of the manuscript for important intellectual content:  Vijayakumar TM, Mohamed Anasdeen S, Shahinaz S

Supervision:  Vijayakumar TM, Shahinaz S
==== Refs
References

1 Non-alcoholic fatty liver disease: global scenario, challenges, and preparedness 8 2024 2023 https://www.worldgastroenterology.org/publications/e-wgn/e-wgn-expert-point-of-view-articles-collection/non-alcoholic-fatty-liver-disease-global-scenario-challenges-and-preparedness
2 Past, present and future perspectives in nonalcoholic fatty liver disease Nat Rev Gastroenterol Hepatol Sanyal AJ 377 386 16 2019 31024089
3 Molecular pathways of nonalcoholic fatty liver disease development and progression Cell Mol Life Sci Bessone F Razori MV Roma MG 99 128 76 2019 30343320
4 Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled fatty liver improvement with rosiglitazone therapy (FLIRT) trial Gastroenterology Ratziu V Giral P Jacqueminet S 100 110 135 2008 18503774
5 Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis Gastroenterology Aithal GP Thomas JA Kaye PV 1176 1184 135 2008 18718471
6 Vitamin E supplementation in the treatment on nonalcoholic fatty liver disease (NAFLD): evidence from an umbrella review of meta-analysis on randomized controlled trials J Dig Dis Wang MY Prabahar K Găman MA Zhang JL 380 389 24 2023 37503812
7 Pharmacokinetics and pharmacodynamics of ursodeoxycholic acid in an overweight population with abnormal liver function Clin Pharmacol Drug Dev Yoon S Lee H Ji SC Yoon SH Cho JY Chung JY 68 77 10 2021 32191400
8 Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial Lancet Younossi ZM Ratziu V Loomba R 2184 2196 394 2019 31813633
9 Discovery of tropifexor (LJN452), a highly potent non-bile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH) J Med Chem Tully DC Rucker PV Chianelli D 9960 9973 60 2017 29148806
10 Efficacy and safety of elafibranor in primary biliary cholangitis N Engl J Med Kowdley KV Bowlus CL Levy C 795 805 390 2024 37962077
11 Saroglitazar, a PPAR-α/γ agonist, for treatment of NAFLD: a randomized controlled double-blind phase 2 trial Hepatology Gawrieh S Noureddin M Loo N 1809 1824 74 2021 33811367
12 Resmetirom: first approval Drugs Keam SJ 729 735 84 2024 38771485
13 Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice Cell Rep Med Desjardins EM Wu J Lavoie DC 101193 4 2023 37729871
14 Prevention of diet-induced metabolic dysregulation, inflammation, and atherosclerosis in Ldlr-/- mice by treatment with the ATP-citrate lyase inhibitor bempedoic acid Arterioscler Thromb Vasc Biol Samsoondar JP Burke AC Sutherland BG 647 656 37 2017 28153881
15 Bempedoic acid lowers low-density lipoprotein cholesterol and attenuates atherosclerosis in low-density lipoprotein receptor-deficient (LDLR+/- and LDLR-/-) Yucatan miniature pigs Arterioscler Thromb Vasc Biol Burke AC Telford DE Sutherland BG 1178 1190 38 2018 29449335
16 Liver-specific ATP-citrate lyase inhibition by bempedoic acid decreases LDL-C and attenuates atherosclerosis Nat Commun Pinkosky SL Newton RS Day EA 13457 7 2016 27892461
17 Efficacy and safety of bempedoic acid added to ezetimibe in statin-intolerant patients with hypercholesterolemia: a randomized, placebo-controlled study Atherosclerosis Ballantyne CM Banach M Mancini GB Lepor NE Hanselman JC Zhao X Leiter LA 195 203 277 2018 29910030
18 Efficacy and safety of bempedoic acid + ezetimibe fixed-dose combination in patients at high CVD risk and with elevated LDL-C receiving maximally tolerated statin therapy Atherosclerosis Ballantyne C Laufs U Ray KK 7 8 287 2019
19 Treatment with ETC-1002 alone and in combination with ezetimibe lowers LDL cholesterol in hypercholesterolemic patients with or without statin intolerance J Clin Lipidol Thompson PD MacDougall DE Newton RS 556 567 10 2016 27206943
20 Efficacy and safety of ETC-1002, a novel investigational low-density lipoprotein-cholesterol-lowering therapy for the treatment of patients with hypercholesterolemia and type 2 diabetes mellitus Arterioscler Thromb Vasc Biol Gutierrez MJ Rosenberg NL Macdougall DE 676 683 34 2014 24385236
21 Efficacy and safety of bempedoic acid in patients with and without metabolic syndrome: pooled analysis of data from four phase 3 clinical trials Atherosclerosis Shapiro MD Taub PR Louie MJ Lei L Ballantyne CM 117182 378 2023 37517922
